Over the past ten years, our
company's operations have centered on accurately simulating the
development and dynamic organization of living tissue and its
constituent cells. Broadly speaking, these efforts impact three
segments of human need: health care, agriculture and energy.
Our activities have focused
on bio-medical research and the development of enabling technologies
to provide life scientists with new, broadly applicable tools: to
investigate stem cell mechanisms, to speed the development of new
drug therapies, or to better understand tissue regeneration, for
example. In addition, the emerging fields of synthetic biology,
bio-engineering, and bio- fuel alternatives provide promising
opportunities in the near future.
Equally exciting is the
portfolio of intellectual property we have derived over the course of
the last decade in developing our core business.
We are an Idaho company with
10 employees and a Board of Directors comprising seven members. There
are nineteen shareholders who own 1.4M shares. Combined funding to
date has totaled more than $9M.
With over 20 patents to date,
both issued and pending, we are making significant technical
contributions in fields such as collision detection used in computer
graphics, complex data profiling, synthetic biology, and cancer
We are beginning the process
of key technology transfers which stand to substantially contribute
to our cash reserves as well as fund the significant growth we have
Through our wholly owned
subsidiary, Endogenics, Inc., we are aggressively pursuing strategic
partnerships and collaborations to augment existing work and expand
into new research in cancer mechanisms, toxicology, stem cell biology
and protein therapeutics.